FBT News and Press, First Trust Amex Biotech Index Fund From 04/20/21

Since U.S. Treasury bonds have fallen more than -20% in value, it looks like we might've seen a short-term bottom and an opportunity to profit in the bond market. Which sectors are performing well in the intermediate term, as well as those that are taking a breather in the short term....

One of my many favorite tools to use when analyzing the markets is a Relative Rotation Graph (or “RRG”). I’m going to focus on using RRG to explain what’s happening under the surface in the market today. You can put any benchmark in the middle, at the z...

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively resilient throughout the pandemic, we expect a full recovery in the latter half of thi...

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12, 36% of the entire US population has received at least one vaccine, and 79% of those ...

Investing in the biotech industry can be a long road to gains given the sector’s volatility. Even with a good understanding of the system, no one can predict which biotechnology treatment, device or therapy will give the biggest return, which makes biotechnology exchange-tr...

In our opinion, telehealth will remain the leading segment of the internet healthcare market as the market shifts away from in-person medical visits. According to Apple CEO Tim Cook, “I believe, if you zoom out into the future, and you look back, and you ask the question, ...

Risk assets continued their historic run last week with EM equities and commodities leading the way. Bonds sold off as the 10-year Treasury note yield broke above 1.20% for the first time since the lows last spring. The 10-year TIPS yield closed the week at 1.02%, near the all-tim...

After a dramatic year of volatility, the U.S. stock market ended 2020 at record highs. Can this momentum continue this year? ESG investments clearly outperformed in 2020. 2021 should be a year of much better cash flow for companies. For further details see: A Stock Picke...

2020 was a busy year for global healthcare with unprecedented efforts to develop vaccines, treatments, and diagnostics for COVID-19. Deal flow in the sector continued to gain momentum in 2020, with M&A transactions and product licensing deals totalling five-year highs as large-cap...

Recent positive developments in COVID-19 vaccines have spurred a wave of market exuberance, lifting share prices of biotech companies at the forefront of the vaccine race. COVID-19 and the urgency to find a cure have opened up opportunities, making the biotech sector a prospective spa...